SPCG 16 Sensi-cab Randomized phase III trial comparing cabazitaxel in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer
Phase of Trial: Phase III
Latest Information Update: 06 May 2016
At a glance
- Drugs Cabazitaxel (Primary) ; LHRH receptor agonists; LHRH receptor antagonists
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms SENSI-CAB
- 07 Jun 2017 Biomarkers information updated
- 10 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01978873).
- 07 Nov 2013 Planned end date changed from 2 Nov 2018 to 1 Nov 2019 as reported by ClinicalTrials.gov record.